Singapore has emerged as a significant player S in the global deep tech landscape. Over the past decade, the government has committed more than S$19 billion to advance research and development in deep tech, according to the Sparkmate report.
There are several initiatives aimed to strengthen the startup landscape in this sector. One key initiative driving Singapore's deep tech agenda is the Singapore Deep-Tech Alliance (SDTA), which facilitates partnerships and provides avenues for companies to create new startups, bring existing ones to market, find solutions to challenges, and access protected technologies. This initiative enhances collaboration and accelerates the growth of deep tech ventures within Singapore's ecosystem.
In addition, Singapore launched A*StartCentral (A*SC) in 2016, a first-of-its-kind open innovation platform by the Agency for Science Technology and Research (A*STAR). It aims to incubate and accelerate the growth of deep tech startups, and serves to bolster the startup ecosystem, including areas such as medtech and life sciences. Now it has over 150 deep tech startups.
"A*StartCentral (A*SC), a key player in Singapore's deep tech ecosystem, empowers earlystage startups in their entrepreneurial journey. By providing guidance and support, A*StartCentral enables startups to expand beyond Singapore and tap into global markets, fostering innovation and entrepreneurship on an international scale," said Emily Liew, Assistant Chief Executive Officer, Innovation & Enterprise Services, Enterprise Singapore.
A*SC builds upon the foundation of an open innovation community to foster crosspollination and interaction amongst researchers, corporates, startups, investors and entrepreneurs across diverse disciplines. A*SC will continue to inspire, innovate with, and empower researcherentrepreneurs in building successful, deep technology enabled ventures.
This story is from the March 2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.
